This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Intergroupe Francophone de Cancerologie Thoracique
ClinicalTrials.gov Identifier:
NCT00198380
First received: September 13, 2005
Last updated: April 28, 2010
Last verified: April 2010
September 13, 2005
April 28, 2010
April 2005
December 2008   (Final data collection date for primary outcome measure)
Disease control rate after 3 months of treatment [ Time Frame: Month ]
Disease control rate after 3 months of treatment
Complete list of historical versions of study NCT00198380 on ClinicalTrials.gov Archive Site
  • Quality of life [ Time Frame: 3-month ]
  • Time to progression [ Time Frame: month ]
  • Survival [ Time Frame: month ]
  • Prediction disease control by clinical and biological markers [ Time Frame: month ]
  • Quality of life
  • Time to progression
  • Survival
  • Prediction disease control by clinical and biological markers
Not Provided
Not Provided
 
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)
Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO classification. Surgery is the best therapy for resectable tumors since the effectiveness of chemotherapy is disappointing. In the advanced P-ADC diffuse/multifocal types of BAC, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) have shown promise, with some rapid, dramatic responses, possibly reflecting specific molecular differences from other non-small cell lung carcinomas.
We therefore conducted a French multicentric phase II trial (IFCT 0401) to evaluate activity and tolerance of gefitinib (250 mg/day) administered as first line treatment in patients with non-resectable P-ADC.
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pneumonic-type Adenocarcinoma (P-ADC)
  • Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Drug: Gefitinib
Gefitinib 250 mg/day, until progression or severe toxicity
Experimental: 1
Intervention: Drug: Gefitinib

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
December 2009
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologically / cytologically proven ADC-P
  • Non-resectable disease
  • 3-month expected survival
  • No prior radiotherapy or chemotherapy
  • Age >= 18 years old
  • Performance status < 4 (WHO)
  • Adequate blood biological parameters

Exclusion Criteria:

  • Abnormal initial fibroscopy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00198380
IFCT-0401
No
Not Provided
Not Provided
Not Provided
Pr Jacques Cadranel, Intergroupe Francophone de Cancérologie Thoracique
Intergroupe Francophone de Cancerologie Thoracique
AstraZeneca
Principal Investigator: Jacques Cadranel, Pr IFCT
Intergroupe Francophone de Cancerologie Thoracique
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP